secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2024-06-11T23:59:59+00:00
Accession:  0001411685-24-000023
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen FY2024 net loss narrows to $29.4M; fasedienol Phase 3 program on track
-------------------------------------------------------------------------------

- Net loss of $29.4M for FY2024, down from $59.2M in FY2023; cash and equivalents $119.2M as of March 31, 2024.
- R&D expenses decreased to $20.0M from $44.4M, primarily due to timing of fasedienol Phase 3 trials.
- PALISADE-3 Phase 3 trial for fasedienol in SAD initiated; PALISADE-4 expected in 2H 2024; positive PALISADE-2 results previously.
- Appointed Cindy Anderson as CFO; entered exclusive negotiation with Fuji Pharma to develop PH80 in Japan for menopausal hot flashes.
- Completed underwritten public offering to fund pipeline milestones; itruvone Phase 2B planning underway for MDD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000141168524000023/0001411685-24-000023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000141168524000023/vtgn-20240611.htm
  HTML page:      https://secwatch.observer/filing/0001411685-24-000023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer